CN119156217A - 治疗神经炎症性病状的方法 - Google Patents

治疗神经炎症性病状的方法 Download PDF

Info

Publication number
CN119156217A
CN119156217A CN202380037527.9A CN202380037527A CN119156217A CN 119156217 A CN119156217 A CN 119156217A CN 202380037527 A CN202380037527 A CN 202380037527A CN 119156217 A CN119156217 A CN 119156217A
Authority
CN
China
Prior art keywords
compound
alkyl
mmol
disease
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380037527.9A
Other languages
English (en)
Chinese (zh)
Inventor
K·彻池
R·泰勒
J·约翰斯顿
H·J·莫必斯
D·波特曼
L·H·卡瓦斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yasina Pharmaceutical Co
Original Assignee
Yasina Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yasina Pharmaceutical Co filed Critical Yasina Pharmaceutical Co
Publication of CN119156217A publication Critical patent/CN119156217A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202380037527.9A 2022-05-04 2023-05-03 治疗神经炎症性病状的方法 Pending CN119156217A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202263338328P 2022-05-04 2022-05-04
US63/338,328 2022-05-04
US202263414111P 2022-10-07 2022-10-07
US63/414,111 2022-10-07
US202263424352P 2022-11-10 2022-11-10
US63/424,352 2022-11-10
US202363447432P 2023-02-22 2023-02-22
US63/447,432 2023-02-22
PCT/US2023/020832 WO2023215377A1 (en) 2022-05-04 2023-05-03 Methods of treating neuroinflammatory conditions

Publications (1)

Publication Number Publication Date
CN119156217A true CN119156217A (zh) 2024-12-17

Family

ID=86693083

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380037527.9A Pending CN119156217A (zh) 2022-05-04 2023-05-03 治疗神经炎症性病状的方法

Country Status (10)

Country Link
US (1) US20250275976A1 (cg-RX-API-DMAC7.html)
EP (1) EP4518865A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025515045A (cg-RX-API-DMAC7.html)
KR (1) KR20250005230A (cg-RX-API-DMAC7.html)
CN (1) CN119156217A (cg-RX-API-DMAC7.html)
AU (1) AU2023263997A1 (cg-RX-API-DMAC7.html)
CA (1) CA3248640A1 (cg-RX-API-DMAC7.html)
IL (1) IL316281A (cg-RX-API-DMAC7.html)
TW (1) TW202406554A (cg-RX-API-DMAC7.html)
WO (1) WO2023215377A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025538382A (ja) * 2022-11-18 2025-11-28 アティラ・ファーマ・インコーポレイテッド 炎症病態を治療する方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
WO2004035587A1 (en) * 2002-10-17 2004-04-29 Myriad Genetics, Inc. Reverse-turn mimetics and composition and methods relating thereto
US20140094413A1 (en) 2012-04-02 2014-04-03 Washington State University Hepatocyte growth factor (hgf) mimics as therapeutic agents
SI3464336T1 (sl) 2016-06-01 2022-06-30 Athira Pharma, Inc. Spojine
AU2021371026A1 (en) * 2020-11-02 2023-06-15 LeonaBio, Inc. Bicyclic compounds and uses thereof for the treatment of diseases
IL313039A (en) * 2021-12-17 2024-07-01 Athira Pharma Inc Uses of bicyclic compounds for the treatment of diseases

Also Published As

Publication number Publication date
CA3248640A1 (en) 2023-11-09
AU2023263997A1 (en) 2024-10-24
IL316281A (en) 2024-12-01
US20250275976A1 (en) 2025-09-04
WO2023215377A1 (en) 2023-11-09
TW202406554A (zh) 2024-02-16
EP4518865A1 (en) 2025-03-12
KR20250005230A (ko) 2025-01-09
JP2025515045A (ja) 2025-05-13

Similar Documents

Publication Publication Date Title
US12246008B2 (en) 4-amino or 4-alkoxy-substituted aryl sulfonamide compounds with selective activity in voltage-gated sodium channels
CN107001378A (zh) 吡咯并嘧啶化合物
CN116568301A (zh) 用于治疗疾病的双环化合物及其用途
JP2025515045A (ja) 神経炎症病態を治療する方法
JP2025515047A (ja) 線維症の治療方法
JP2024546600A (ja) 疾患の治療のための二環式化合物の使用
US20250161308A1 (en) Methods of Treating Covid-Related Disorders
CN119300834A (zh) 治疗神经病变的方法
CN113226321A (zh) 吡唑基化合物及其使用方法
CN118382441A (zh) 双环化合物用于治疗疾病的用途
EA050745B1 (ru) Применение бициклических соединений для лечения заболеваний
EA049703B1 (ru) Бициклические соединения и их применение для лечения заболеваний
WO2025250930A1 (en) Hdac6 inhibitors and method of their use
TW202031264A (zh) 用於治療疼痛和疼痛相關疾病的新穎烷氧基氨基吡啶衍生物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Country or region after: U.S.A.

Address after: Washington State

Applicant after: Liona Biotechnology Co.,Ltd.

Address before: Washington State

Applicant before: Yasina Pharmaceutical Co.

Country or region before: U.S.A.